New England Journal of Medicine· 2012Q1
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- 1,336citations
- Q1SCImago
- 2012year
Short summary
Oral BG-12 (dimethyl fumarate) significantly reduced relapse rates by 44-51% compared to placebo in relapsing-remitting multiple sclerosis patients over 2 years, with similar efficacy to glatiramer acetate.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine